TY - CHAP M1 - Book, Section TI - Surgical Treatment of Thoracic Fungal Infections A1 - Adams, Ann A1 - Gill, Ritu R. A1 - McNamee, Ciaran J. A2 - Sugarbaker, David J. A2 - Bueno, Raphael A2 - Colson, Yolonda L. A2 - Jaklitsch, Michael T. A2 - Krasna, Mark J. A2 - Mentzer, Steven J. A2 - Williams, Marcia A2 - Adams, Ann PY - 2015 T2 - Adult Chest Surgery, 2e AB - Thoracic fungal infections have a complex and variable presentation, ranging from benign self-limited processes, which spontaneously resolve, to severe life-threatening infections associated with disabling morbidity and high mortality. Persistent fungal infections in normal individuals may either resolve without producing symptoms, or worsen leading to severe complications of hemoptysis, mediastinal fibrosis, empyema, and meningitis. Immune-compromised hosts demonstrate greater susceptibility to fungi than normal individuals and have more severe outcomes including vascular invasion, septicemia with fungal dissemination, organ infarction, and death. Adding to this complexity, the epidemiology of fungal disease is constantly changing as species emerge or relocate or increase in virulence. Early intervention can improve survival and in some cases obviate the necessity of surgery. It is critical therefore to recognize the clinical manifestations of thoracic fungal infection early in its clinical course. Fortunately, recent advances in knowledge concerning fungal biology including the functional genome, the structure of the cell wall and membrane, and the use of molecular and epidemiologic techniques have led to rapid identification of pathogens and the institution of effective, less toxic antifungal agents.1 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/15 UR - accesssurgery.mhmedical.com/content.aspx?aid=1105844180 ER -